Thomas Stewart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas Stewart has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Christopher John Lindsell
Duke University
4 shared publications Andrew Toler
National Center for Advancing Translational Science (NCATS) Bethesda Maryland USA
2 shared publications- Carolyn T. Bramante
University of Minnesota, Minneapolis, MN, USA
2 shared publications - Clarence Buddy Creech Ii
Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, United States
2 shared publications - David R. Boulware
University of Minnesota, Minneapolis, USA
2 shared publications David Sahner
National Center for Advancing Translational Science (NCATS) Bethesda Maryland USA
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Our objective was to evaluate metformin prescribed at the time of SARS‐CoV‐2 infection on the risk of developing Long COVID (LC) in electronic health record data. We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0–6 months and the 6–12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log‐linear model. After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS‐CoV‐2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. With the aRR of 0.47 (95% CI 0.25–0.89), any risk reduction between 75% and 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant‐report.
- 29 October 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Open AccessMetformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Our objective was to evaluate metformin prescribed at the time of SARS‐CoV‐2 infection on the risk of developing Long COVID (LC) in electronic health record data. We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0–6 months and the 6–12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log‐linear model. After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS‐CoV‐2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. With the aRR of 0.47 (95% CI 0.25–0.89), any risk reduction between 75% and 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant‐report.
- Open Access
- 26 November 2025
- Published by Wiley
Metformin at the time of Covid-19 infection and risk of Long Covid: A Target Trial Emulation Study
Background : Our objective was to evaluate metformin prescribed at the time of SARS-CoV-2 infection on the risk of developing Long Covid (LC) in electronic health record data. Methods : We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory coronavirus syndrome 2 (SARS-CoV- 2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0- 6 months and the 6-12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0-6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log linear model. Results : After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D vs. 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25 to 0.89). For prescriptions on Days 0-1 relative to infection, aRR was 0.39 (95% CI 0.12-1.24); for prescriptions on Days 0-14 the aRR was 0.75 (95% CI 0.52-1.08). Conclusions : In this observational analysis, metformin prescribed within a week of documented SARS-CoV-2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. Any risk reduction between 75% to 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant-report.
- 26 November 2025
- Published by Wiley
Open AccessMetformin at the time of Covid-19 infection and risk of Long Covid: A Target Trial Emulation Study
Background : Our objective was to evaluate metformin prescribed at the time of SARS-CoV-2 infection on the risk of developing Long Covid (LC) in electronic health record data. Methods : We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory coronavirus syndrome 2 (SARS-CoV- 2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0- 6 months and the 6-12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0-6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log linear model. Results : After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D vs. 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25 to 0.89). For prescriptions on Days 0-1 relative to infection, aRR was 0.39 (95% CI 0.12-1.24); for prescriptions on Days 0-14 the aRR was 0.75 (95% CI 0.52-1.08). Conclusions : In this observational analysis, metformin prescribed within a week of documented SARS-CoV-2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. Any risk reduction between 75% to 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant-report.
- Open Access
- 16 April 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-26
Participant experiences in a decentralized clinical trial using digital health technologies: The ACTIV-6 study
Background: Inadequate recruitment and retention impede clinical trial goals. Emerging decentralized clinical trials (DCTs) leveraging digital health technologies (DHTs) for remote recruitment and data collection aim to address barriers to participation in traditional trials. The ACTIV-6 trial is a DCT using DHTs, but participants’ experiences of such trials remain largely unknown. This study explored participants’ perspectives of the ACTIV-6 DCT that tested outpatient COVID-19 therapeutics. Methods: Participants in the ACTIV-6 study were recruited via email to share their day-to-day trial experiences during 1-hour virtual focus groups. Two human factors researchers guided group discussions through a semi-structured script that probed expectations and perceptions of study activities. Qualitative data analysis was conducted using a grounded theory approach with open coding to identify key themes. Results: Twenty-eight ACTIV-6 study participants aged 30+ years completed a virtual focus group including 1–4 participants each. Analysis yielded three major themes: perceptions of the DCT experience, study activity engagement, and trust. Participants perceived the use of remote DCT procedures supported by DHTs as an acceptable and efficient method of organizing and tracking study activities, communicating with study personnel, and managing study medications at home. Use of social media was effective in supporting geographically dispersed participant recruitment but also raised issues with trust and study legitimacy. Conclusions: While participants in this qualitative study viewed the DCT-with-DHT approach as reasonably efficient and engaging, they also identified challenges to address. Understanding facilitators and barriers to DCT participation and DHT interaction can help improve future research design.
- 16 April 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , 1-26
Open AccessParticipant experiences in a decentralized clinical trial using digital health technologies: The ACTIV-6 study
Background: Inadequate recruitment and retention impede clinical trial goals. Emerging decentralized clinical trials (DCTs) leveraging digital health technologies (DHTs) for remote recruitment and data collection aim to address barriers to participation in traditional trials. The ACTIV-6 trial is a DCT using DHTs, but participants’ experiences of such trials remain largely unknown. This study explored participants’ perspectives of the ACTIV-6 DCT that tested outpatient COVID-19 therapeutics. Methods: Participants in the ACTIV-6 study were recruited via email to share their day-to-day trial experiences during 1-hour virtual focus groups. Two human factors researchers guided group discussions through a semi-structured script that probed expectations and perceptions of study activities. Qualitative data analysis was conducted using a grounded theory approach with open coding to identify key themes. Results: Twenty-eight ACTIV-6 study participants aged 30+ years completed a virtual focus group including 1–4 participants each. Analysis yielded three major themes: perceptions of the DCT experience, study activity engagement, and trust. Participants perceived the use of remote DCT procedures supported by DHTs as an acceptable and efficient method of organizing and tracking study activities, communicating with study personnel, and managing study medications at home. Use of social media was effective in supporting geographically dispersed participant recruitment but also raised issues with trust and study legitimacy. Conclusions: While participants in this qualitative study viewed the DCT-with-DHT approach as reasonably efficient and engaging, they also identified challenges to address. Understanding facilitators and barriers to DCT participation and DHT interaction can help improve future research design.
- Open Access
Health literacy and all‐cause mortality among cancer patients
Background: The association between health literacy and all‐cause mortality among cancer patients remains unclear.Methods: This is a retrospective cohort study of 9603 patients diagnosed with prostate, lung, breast, renal, colorectal, brain, head and neck, bladder, pancreatic, liver, sarcoma, and gastric cancers who were screened for health literacy between 2008 and 2018, using the Brief Health Literacy Screen (BHLS). Higher scores (range, 3–15) indicate higher health literacy. The association between all‐cause mortality and health literacy was estimated using multivariable Cox proportional hazards models.Results: A total of 8608 (89%) patients were non‐Hispanic White. The median follow‐up was 3.1 years. Patients with a BHLS score of 15 had a median survival improvement of 9.4 months (95% confidence interval [CI], 6.0–13.2 months) compared to those with a score of 9. Lower BHLS scores (9 vs. 15) were associated with higher mortality in stages II (adjusted hazard ratio [aHR], 2.6 [95% CI, 1.5–5.1]) and III (aHR 2.9 [95% CI, 1.4‐6.0]) prostate cancer; stages I (aHR 1.7 [95% CI, 1.1–2.5]) and IV (aHR, 1.6 [95% CI, 1.2–2.1]) lung cancer; stage I colorectal cancer (aHR, 2.2 [95% CI, 1.3–4.7]); stage I renal cancer (aHR, 1.8 [95% CI, 1.1–3.4]); stages I (aHR, 2.6 [95% CI, 1.3–7.1]) and IV (aHR, 1.7 [95% CI, 1.2–2.7]) head and neck cancer; stage II bladder cancer (aHR, 1.6 [95% CI, 1.0–2.8]); stage I liver cancer (aHR, 4.1 [95% CI, 1.9–9.3]); and all stages of breast cancer.Conclusions: Lower health literacy was associated with higher all‐cause mortality among patients with 12 different types of cancer, varying by cancer type and stage.
Open AccessHealth literacy and all‐cause mortality among cancer patients
Background: The association between health literacy and all‐cause mortality among cancer patients remains unclear.Methods: This is a retrospective cohort study of 9603 patients diagnosed with prostate, lung, breast, renal, colorectal, brain, head and neck, bladder, pancreatic, liver, sarcoma, and gastric cancers who were screened for health literacy between 2008 and 2018, using the Brief Health Literacy Screen (BHLS). Higher scores (range, 3–15) indicate higher health literacy. The association between all‐cause mortality and health literacy was estimated using multivariable Cox proportional hazards models.Results: A total of 8608 (89%) patients were non‐Hispanic White. The median follow‐up was 3.1 years. Patients with a BHLS score of 15 had a median survival improvement of 9.4 months (95% confidence interval [CI], 6.0–13.2 months) compared to those with a score of 9. Lower BHLS scores (9 vs. 15) were associated with higher mortality in stages II (adjusted hazard ratio [aHR], 2.6 [95% CI, 1.5–5.1]) and III (aHR 2.9 [95% CI, 1.4‐6.0]) prostate cancer; stages I (aHR 1.7 [95% CI, 1.1–2.5]) and IV (aHR, 1.6 [95% CI, 1.2–2.1]) lung cancer; stage I colorectal cancer (aHR, 2.2 [95% CI, 1.3–4.7]); stage I renal cancer (aHR, 1.8 [95% CI, 1.1–3.4]); stages I (aHR, 2.6 [95% CI, 1.3–7.1]) and IV (aHR, 1.7 [95% CI, 1.2–2.7]) head and neck cancer; stage II bladder cancer (aHR, 1.6 [95% CI, 1.0–2.8]); stage I liver cancer (aHR, 4.1 [95% CI, 1.9–9.3]); and all stages of breast cancer.Conclusions: Lower health literacy was associated with higher all‐cause mortality among patients with 12 different types of cancer, varying by cancer type and stage.
- Open Access
- 15 October 2024
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 8 (1) , e155
The statistical design and analysis of pandemic platform trials: Implications for the future
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a future pandemic. The ACTIV master protocols were designed to rapidly assess what treatments might save lives, keep people out of the hospital, and help them feel better faster. Study teams initially worked without knowledge of the natural history of disease and thus without key information for design decisions. Moreover, the science of platform trial design was in its infancy. Here, we discuss the statistical design choices made and the adaptations forced by the changing pandemic context. Lessons around critical aspects of trial design are summarized, and recommendations are made for the organization of master protocols in the future.
- 15 October 2024
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 8 (1) , e155
Open AccessThe statistical design and analysis of pandemic platform trials: Implications for the future
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a future pandemic. The ACTIV master protocols were designed to rapidly assess what treatments might save lives, keep people out of the hospital, and help them feel better faster. Study teams initially worked without knowledge of the natural history of disease and thus without key information for design decisions. Moreover, the science of platform trial design was in its infancy. Here, we discuss the statistical design choices made and the adaptations forced by the changing pandemic context. Lessons around critical aspects of trial design are summarized, and recommendations are made for the organization of master protocols in the future.
- Open Access
- 9 June 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (18) , 3539-3561
Bayesian transition models for ordinal longitudinal outcomes
Ordinal longitudinal outcomes are becoming common in clinical research, particularly in the context of COVID‐19 clinical trials. These outcomes are information‐rich and can increase the statistical efficiency of a study when analyzed in a principled manner. We present Bayesian ordinal transition models as a flexible modeling framework to analyze ordinal longitudinal outcomes. We develop the theory from first principles and provide an application using data from the Adaptive COVID‐19 Treatment Trial (ACTT‐1) with code examples in R. We advocate that researchers use ordinal transition models to analyze ordinal longitudinal outcomes when appropriate alongside standard methods such as time‐to‐event modeling.
- 9 June 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (18) , 3539-3561
Open AccessBayesian transition models for ordinal longitudinal outcomes
Ordinal longitudinal outcomes are becoming common in clinical research, particularly in the context of COVID‐19 clinical trials. These outcomes are information‐rich and can increase the statistical efficiency of a study when analyzed in a principled manner. We present Bayesian ordinal transition models as a flexible modeling framework to analyze ordinal longitudinal outcomes. We develop the theory from first principles and provide an application using data from the Adaptive COVID‐19 Treatment Trial (ACTT‐1) with code examples in R. We advocate that researchers use ordinal transition models to analyze ordinal longitudinal outcomes when appropriate alongside standard methods such as time‐to‐event modeling.
- Open Access
- 29 January 2024
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 8 (1) , e19
Progress toward realizing the promise of decentralized clinical trials
- 29 January 2024
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 8 (1) , e19
Open AccessProgress toward realizing the promise of decentralized clinical trials
- Open Access
- 19 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (8) , e022723
Tissue Sodium in Patients With Early Stage Hypertension: A Randomized Controlled Trial
Background: Sodium (Na + ) stored in skin and muscle tissue is associated with essential hypertension. Sodium magnetic resonance imaging is a validated method of quantifying tissue stores of Na + . In this study, we evaluated tissue Na + in patients with elevated blood pressure or stage I hypertension in response to diuretic therapy or low Na + diet. Methods and Results: In a double‐blinded, placebo‐controlled trial, patients with systolic blood pressure 120 to 139 mm Hg were randomized to low sodium diet (+ using sodium magnetic resonance imaging and pulse wave velocity were assessed at the beginning and end of the study. Ninety‐eight patients were enrolled to undergo baseline measurements and 54 completed randomization. Median baseline muscle and skin Na + in 98 patients were 16.4 mmol/L (14.9, 18.9) and 13.1 mmol/L (11.1, 16.1), respectively. After 8 weeks, muscle Na + increased in the diet and chlorthalidone arms compared with placebo. Skin sodium was decreased only in the diet arm compared with placebo. These associations remained significant after adjustment for age, sex, body mass index, systolic blood pressure, and urinary sodium. No changes were observed in pulse wave velocity among the different groups when compared with placebo. Conclusions: Diuretic therapy for 8 weeks did not decrease muscle or skin sodium or improve pulse wave velocity in patients with elevated blood pressure or stage I hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02236520.
- 19 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (8) , e022723
Open AccessTissue Sodium in Patients With Early Stage Hypertension: A Randomized Controlled Trial
Background: Sodium (Na + ) stored in skin and muscle tissue is associated with essential hypertension. Sodium magnetic resonance imaging is a validated method of quantifying tissue stores of Na + . In this study, we evaluated tissue Na + in patients with elevated blood pressure or stage I hypertension in response to diuretic therapy or low Na + diet. Methods and Results: In a double‐blinded, placebo‐controlled trial, patients with systolic blood pressure 120 to 139 mm Hg were randomized to low sodium diet (+ using sodium magnetic resonance imaging and pulse wave velocity were assessed at the beginning and end of the study. Ninety‐eight patients were enrolled to undergo baseline measurements and 54 completed randomization. Median baseline muscle and skin Na + in 98 patients were 16.4 mmol/L (14.9, 18.9) and 13.1 mmol/L (11.1, 16.1), respectively. After 8 weeks, muscle Na + increased in the diet and chlorthalidone arms compared with placebo. Skin sodium was decreased only in the diet arm compared with placebo. These associations remained significant after adjustment for age, sex, body mass index, systolic blood pressure, and urinary sodium. No changes were observed in pulse wave velocity among the different groups when compared with placebo. Conclusions: Diuretic therapy for 8 weeks did not decrease muscle or skin sodium or improve pulse wave velocity in patients with elevated blood pressure or stage I hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02236520.
- Open Access
- 5 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (1) , 1-9
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
Isocitrate dehydrogenase (IDH) mutations in low-grade gliomas (LGG) result in improved survival and DNA hypermethylation compared with IDH wild-type LGGs. IDH-mutant LGGs become hypomethylated during progression. It is uncertain whether methylation changes occur during IDH wild-type GBM progression and whether the methylome can be reprogrammed. This phase I study evaluated the safety, tolerability, efficacy, and methylome changes after l-methylfolate (LMF) treatment, in combination with temozolomide and bevacizumab in patients with recurrent high-grade glioma. Fourteen patients total, 13 with GBM, one with anaplastic astrocytoma, all IDH wild-type were enrolled in the study. All patients received LMF at either 15, 30, 60, or 90 mg daily plus temozolomide (75 mg/m2 5 days per month) and bevacizumab (10 mg/kg every two weeks).No MTD was identified. LMF-treated patients had median overall survival of 9.5 months [95% confidence interval (CI), 9.1–35.4] comparable with bevacizumab historical control 8.6 months (95% CI, 6.8–10.8). Six patients treated with LMF survived more than 650 days. Across all treatment doses, the most adverse events were diarrhea (7%, 1 patient, grade 2), reflux (7%, 1 patient, grade 2), and dysgeusia (7%, 1 patient, grade 2). In the six brains donated at death, there was a 25% increase in DNA methylated CpGs compared with the paired initial tumor. LMF in combination with temozolomide and bevacizumab was well tolerated in patients with recurrent IDH wild-type high-grade glioma. This small study did not establish a superior efficacy with addition of LMF compared with standard bevacizumab therapy; however, this study did show methylome reprogramming in high-grade glioma. Significance: Glioblastoma (GBM) is a primary brain tumor with a poor prognosis. Therapies to date have failed to improve survival. LGGs, with IDH mutations, have increased global DNA methylation and increased survival compared with GBMs. GBMs lack this mutation and have less DNA methylation. Here we show that the DNA methylome can be modified in GBM with LMF. Such treatment might be useful in methylome priming prior to immunotherapy.
- 5 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (1) , 1-9
Open AccessPhase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
Isocitrate dehydrogenase (IDH) mutations in low-grade gliomas (LGG) result in improved survival and DNA hypermethylation compared with IDH wild-type LGGs. IDH-mutant LGGs become hypomethylated during progression. It is uncertain whether methylation changes occur during IDH wild-type GBM progression and whether the methylome can be reprogrammed. This phase I study evaluated the safety, tolerability, efficacy, and methylome changes after l-methylfolate (LMF) treatment, in combination with temozolomide and bevacizumab in patients with recurrent high-grade glioma. Fourteen patients total, 13 with GBM, one with anaplastic astrocytoma, all IDH wild-type were enrolled in the study. All patients received LMF at either 15, 30, 60, or 90 mg daily plus temozolomide (75 mg/m2 5 days per month) and bevacizumab (10 mg/kg every two weeks).No MTD was identified. LMF-treated patients had median overall survival of 9.5 months [95% confidence interval (CI), 9.1–35.4] comparable with bevacizumab historical control 8.6 months (95% CI, 6.8–10.8). Six patients treated with LMF survived more than 650 days. Across all treatment doses, the most adverse events were diarrhea (7%, 1 patient, grade 2), reflux (7%, 1 patient, grade 2), and dysgeusia (7%, 1 patient, grade 2). In the six brains donated at death, there was a 25% increase in DNA methylated CpGs compared with the paired initial tumor. LMF in combination with temozolomide and bevacizumab was well tolerated in patients with recurrent IDH wild-type high-grade glioma. This small study did not establish a superior efficacy with addition of LMF compared with standard bevacizumab therapy; however, this study did show methylome reprogramming in high-grade glioma. Significance: Glioblastoma (GBM) is a primary brain tumor with a poor prognosis. Therapies to date have failed to improve survival. LGGs, with IDH mutations, have increased global DNA methylation and increased survival compared with GBMs. GBMs lack this mutation and have less DNA methylation. Here we show that the DNA methylome can be modified in GBM with LMF. Such treatment might be useful in methylome priming prior to immunotherapy.